Aptose Biosciences Inc.APS.TO
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX · Canada · aptose.com
Aptose Biosciences Inc. is a Toronto-based clinical-stage biotechnology company developing oral kinase inhibitors for hematologic malignancies. Its lead asset tuspetinib (HM43239) has completed Phase 1/2 clinical trials targeting acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (MDS).
Key ratios
ROA
-153.5%TTM
2025
-153.5%2024
-142.0%2023
-102.2%
ROE
-694.1%TTM
2023
-294.0%
Recent news
Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation
Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical
Aptose Reports First Quarter 2026 Results
Track APS.TO in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer